SCHEMBL1883383

SCHEMBL1883383

O=C(NC1CCCCC1)C(c1cccs1)N(C(=O)CCl)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.53
KDM4E B2RXH2 1/20 0.53
LMNA P02545 1/20 0.53
SMN1; SMN2 Q16637 3/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
PRNP P04156 1/20 0.51
ALDH1A1 P00352 5/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
YAP1 P46937 1/20 0.49
TEAD4 Q15561 1/20 0.49
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
USP2 O75604 1/20 0.47
TSHR P16473 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15189099 0.91 SMN1; SMN2 (0.54) MAPTKDM4ELMNASMN1; SMN2MEN1
SCHEMBL1886649 0.91 MAPT (0.53) MAPTKDM4ELMNASMN1; SMN2MEN1
SCHEMBL1887723 0.89 MAPT (0.54) MAPTKDM4ELMNASMN1; SMN2MEN1
SCHEMBL1888399 0.89 MAPT (0.62) MAPTKDM4ELMNASMN1; SMN2MEN1
SCHEMBL1882201 0.87 SMN1; SMN2 (0.56) MAPTKDM4ELMNASMN1; SMN2MEN1
SCHEMBL1887127 0.86 YAP1 (0.66) MAPTKDM4ELMNASMN1; SMN2MEN1
SCHEMBL1882881 0.86 SMN1; SMN2 (0.53) MAPTKDM4ELMNASMN1; SMN2MEN1
SCHEMBL12639363 0.86 SMN1; SMN2 (0.52) MAPTKDM4ELMNASMN1; SMN2MEN1
SCHEMBL12672320 0.86 TDP1 (0.57) MAPTKDM4ELMNASMN1; SMN2MEN1
SCHEMBL1568436 0.83 PRNP (0.49) MAPTKDM4ELMNASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8519188-B2 Compounds which can be used for the treatment of cancers Marc-Henry Pitty (FR) 2013-08-27 US disclosed
US-8519188-B2 Compounds which can be used for the treatment of cancers Marc-Henry Pitty (FR) 2013-08-27 US disclosed
US-8519188-B2 Compounds which can be used for the treatment of cancers Marc-Henry Pitty (FR) 2013-08-27 US disclosed
EP-2307017-B1 COMPOUNDS WHICH CAN BE USED FOR THE TREATMENT OF CANCERS PITTY MARC HENRY (FR) 2013-08-14 EP disclosed
US-20110104162-A1 Compounds which can be used for the Treatment of Cancers CYTOMICS SYSTEMS (FR) 2011-05-05 US disclosed
US-20110104162-A1 Compounds which can be used for the Treatment of Cancers CYTOMICS SYSTEMS (FR) 2011-05-05 US disclosed
US-20110104162-A1 Compounds which can be used for the Treatment of Cancers CYTOMICS SYSTEMS (FR) 2011-05-05 US disclosed
WO-2009150248-A1 COMPOUNDS WHICH CAN BE USED FOR THE TREATMENT OF CANCERS CYTOMICS SYSTEMS (FR) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110104162-A1 Compounds which can be used for the Treatment of Cancers VHL, CYP11B2, SLC10A1 MAPT 2578/4885KDM4E 4220/4885LMNA 2955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.